- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04382573
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. (CDK13)
CDK13 Related Disorder : Clinical Phenotype, Neuropsychological Profile, Brain MRI Characteristics and Epigenetic Signature.
CDK13 related disorder is mainly characterised by developmental delay (DD) and intellectual disability (ID), ranging from mild to severe, and malformation syndrome.
The aims of this study are first to better delineate the clinical phenotype, as well as the neuropsychological profile, and the brain MRI characteristics; and, second, to study the epigenetic signatures in a cohort of individuals with CDK13 intragenic pathogenic variants. This work will conduct to a MD thesis of a clinical resident geneticist in France.
Physician that will participate will fill an Excel sheet regarding the clinical and neuropsychological assessment.
The investigators will be also happy to have either CD-ROM or a link to have access to the brain MRI data as well as a DNA sample with a minimum 0.5ug of peripheral blood genomic DNA. The investigators will gather the DNA in Montpellier genetic lab (Dr Mouna BARAT) and send the batch to the Dr Sadikovic' lab.
Between 2019 and 2020, The investigators have already recruited data from individuals with CDK13 pathogenic variants from France and several European genetic centres.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators aim to better understand and delineate the genetic syndrome CDK13 This genetic disorder was described in Sepember 2016 in Nature Genetics (PMID 27479907).
Since this first publication of 6 individuals carrying the pathogenic mutation CDK13, 37 other individuals carrying a pathogenic mutation of CDK13 have been reported in the litterature The investigators are seeking to better define the phenotype of individuals with pathogenic variants of CDK13, to better understand intellectual functioning as well as the strengths and weaknesses of intellectual functioning by collecting standardized neuropsychological assessments already performed such as WPPSI/WISC and WAIS. For this purpose, The investigators will gather clinical and neuropsychological data already carried out in the context of care.
The investigators also aim to gather the cerebral MRI scans already performed in order to better delimit the cerebral anomalies observed in individuals and if the sequence is adapted, The investigators will perform VBM studies.
Finally, The investigators will attempt to identify an epigenetic signature in this genetic disease. To this end, The investigators will collect genomic DNA from peripheral blood already collected for genetic analysis and send an anonymized batch of samples to our collaborator, Dr. Bekim Sadicovik. Dr. Bekim Sadicovik and his team will compare the epigenetic DNA methylation-type markers with the corresponding sex and age controls. If specific probes are abnormally methylated in CDK13 individuals, this will determine a disease-specific epigenetic signature. The investigators will then be able to propose an epigenetic signature for individuals with uncharacterized CDK13 variations (class 3, VUS). This method will make it possible to define whether the variation is responsible for the disease or not without going through functional analysis steps that are difficult to implement routinely.
The expected benefits are a better understanding of CDK13 disease, keys to neuropsychological rehabilitation, a better understanding of human brain functions, the possibility of proposing an epigenetic signature for people in whom it is not possible to decide whether a variation in the CDK13 gene is pathological or not
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: David GENEVIEVE, MH PD
- Phone Number: 33 04 67 33 61 04
- Email: d-genevieve@chu-montpellier.fr
Study Contact Backup
- Name: Flavien ROUXEL, resident
- Email: f-rouxel@chu-montpellier.fr
Study Locations
-
-
-
Montpellier, France, 34295
- Recruiting
- UH Montpellier
-
Contact:
- David GENEVIEVE
- Email: d-genevieve@chu-montpellier.fr
-
Contact:
- Flavien ROUXEL
- Email: f-rouxel@chu-montpellier.fr
-
Sub-Investigator:
- Bekim SADIKOVIC, DR
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- CDK13 intragenic pathogenic SNV (Single Nucleotide Variant)
Exclusion criteria:
- no pathogenic SNV in CDK13
- no consent for the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CDK13
CDK13 intragenic pathogenic variant
|
Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of clinical data
Time Frame: 1 day
|
Clinical data such as growth parameters, facial, neurological, ENT, eye, cardiac, etc.. features
|
1 day
|
Neuropsychological test
Time Frame: 1 day
|
Neuropsychological test with total IQ and subscore data using WISC or WAIS test
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of genetic data
Time Frame: 1 day
|
Evolution of genetic data : Epigenetic signatures
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David GENEVIEVE, Department of Medical Genetics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECHMPL20_0279
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Heart Defects
-
Oslo University HospitalUniversity of BergenCompletedHeart Septal Defects, Atrial | Heart Defects,CongenitalNorway
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Heart Septal Defects, Atrial | Heart Septal Defects, Ventricular | Endocardial Cushion Defects | Defect, Congenital Heart
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Heart Septal Defects, Atrial | Heart Septal Defects, Ventricular | Endocardial Cushion Defects | Defect, Congenital Heart
-
Assiut UniversityNot yet recruitingCardiac Congenital Defects
-
SeptRx, Inc.UnknownHeart Septal Defects | Heart Defects, Congenital | Foramen Ovale, PatentGermany, France
-
Medtronic Heart ValvesCompletedDysfunctional RVOT Conduits in Patients With Congenital Heart DefectsSpain, United States, Austria, Canada
-
Zhengzhou UniversityNot yet recruitingCongenital Heart DefectChina
-
Children's Hospital of Eastern OntarioHeart and Stroke Foundation of CanadaRecruitingCongenital Heart DefectCanada
-
Medical College of WisconsinNational Center for Research Resources (NCRR); Children's Hospital and Health...Terminated
-
Ain Shams UniversityCompletedHeart Defects, CongenitalEgypt
Clinical Trials on Epigenetic signatures
-
University Hospital, MontpellierUnknown
-
University Hospital, MontpellierCompletedIntellectual Developmental Disorder | BCL11B Related DisorderFrance
-
University Hospital, MontpellierAssociation Xtraordinaire sub-group DDX3X; GenidaUnknownIntellectual Developmental Disorder | X-LINKEDFrance
-
University of LorraineLigue contre le cancer, FranceRecruitingQuality of Life | Cancer, Breast | Resilience, Psychological | Adverse Childhood Experiences | Attachment Styles | Epigenesis, GeneticFrance
-
IRCCS Policlinico S. DonatoRecruitingMarfan Syndrome | Marfan's Syndrome With Cardiovascular ManifestationsItaly
-
hz ClinicEast London Electric Company; PropDesk; MedCity; UCL Partners; Imperial College London... and other collaboratorsRecruitingPain | Stress | Ageing Signs | Immunity CompromiseUnited Kingdom
-
University Hospital, AngersNot yet recruitingPrimary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative NeoplasmFrance
-
University Hospital FreiburgRecruitingHelicobacter Pylori InfectionGermany
-
Università Vita-Salute San RaffaeleRecruitingFemale InfertilityItaly
-
University Hospital, BordeauxRecruiting